Home / Market News / $IMTX
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

Immatics Presents Clinical Activity of IMA402 and IMA203CD8 at ESMO 2026

Oct 24, 2026, 7:03 PM UTC · Primary ticker $IMTX

Immatics presented promising clinical results for its PRAME-targeting bispecific IMA402, showing high response rates and survival in melanoma. The company also provided updates on its cell therapy IMA203CD8, including phase 1a completion and plans for pediatric cancer trials, indicating significant progress in its oncology pipeline.

Immatics (IMTX) announced compelling clinical data for its PRAME-targeting bispecific IMA402, demonstrating a 32% cORR, 12.5 months median DOR, and 91% 1-year OS in advanced melanoma patients. This data is highly positive, suggesting a potentially effective new treatment for a difficult-to-treat cancer. Additionally, the completion of Phase 1a dose escalation for IMA203CD8 and plans for a pediatric cancer trial expand the potential market for their cell therapy. This news is a significant short-term positive catalyst for IMTX, validating its platform and pipeline. Long-term, successful further development and commercialization of these therapies could establish Immatics as a leader in PRAME-targeted oncology, offering a substantial opportunity for investors.

$IMTX positive Strong clinical data for lead candidates
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.